Search results
Parallel Advisors LLC Sells 169 Shares of AstraZeneca PLC (NASDAQ:AZN)
ETF DAILY NEWS· 2 days agoParallel Advisors LLC reduced its stake in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 1.2% during the fourth quarter, according to the company in its most recent 13F filing ...
AstraZeneca’s (AZN) “Buy” Rating Reaffirmed at Citigroup
ETF DAILY NEWS· 4 days agoCitigroup reissued their buy rating on shares of AstraZeneca (LON:AZN – Free Report) in a report published on Tuesday, Marketbeat reports. Several other analysts have also ...
This Pharma Stock Is Poised to Keep Outperforming the S&P 500 | The Motley Fool
The Motley Fool· 2 days agoAstraZeneca (AZN 1.23%), recognized as the world's sixth-largest pharmaceutical entity by market...
Amgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca's Drug
Benzinga via Yahoo Finance· 3 days agoTuesday, the FDA approved Amgen Inc (NASDAQ:AMGN) Bkemv (eculizumab-aeeb) as the first...
AstraZeneca Plans to Rake in $80 Billion by 2030. Should You Buy the Stock? | The Motley Fool
The Motley Fool· 3 days agoAstraZeneca (AZN -0.70%) is embarking on a fresh business plan that will see it grow significantly...
AstraZeneca CEO Has No Plans to Retire as He Seeks to Nearly Double Sales by 2030
The Wall Street Journal· 1 day agolongest-serving chief executive, Pascal Soriot, has no plans to step down for now as the company...
AstraZeneca shares target raised by Argus on new drug approvals By Investing.com
Investing.com· 2 days agoOn Thursday, AstraZeneca PLC (NASDAQ:LON:AZN) shares received an updated price target from a market...
JPMorgan bullish on AstraZeneca stock, highlights AZD0780's sales By Investing.com
Investing.com· 4 days agoOn Tuesday, JPMorgan (NYSE:JPM) maintained its positive stance on AstraZeneca (NASDAQ:AZN:LN)...
Pharma Stock Roundup: JNJ, MRK M&A Deals, SNY, RHHBY Drugs' Priority Review & More
Zacks via Yahoo Finance· 1 day agoJ&J (JNJ) and Merck (MRK) announce the acquisitions of private biotechs. The FDA grants Priority...
... Record $44.1B Licensing Deals With Chinese Drugmakers In 2023: Report - AstraZeneca (NASDAQ:AZN...
Benzinga· 5 days agoWestern pharmaceutical companies and investors are driving a record number of licensing deals with...